Semaglutide denied as experimental or investigational by Humana?

Humana's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Semaglutide as Experimental

An experimental or investigational denial from Humana means Humana's clinical policy team has determined that the evidence supporting semaglutide for your specific prescribed use does not satisfy Humana's internal standard for coverage as an established therapy. This most commonly occurs when semaglutide is prescribed for an indication that Humana's current medical policy has not yet recognized as covered — whether because the indication is off-label, because it was recently FDA-approved and Humana's policy has not yet been updated, or because the plan's policy language is narrower than the full scope of the FDA approval.

## Why This Denial Is Appealable

Semaglutide holds multiple FDA approvals. If your prescribed indication falls within an FDA-approved use, the experimental classification is factually inconsistent with the regulatory record, and the denial should be reversed. For recently approved indications, Humana's policy may simply be lagging behind the FDA's determination — an appeal that presents the FDA approval clearly and directly is often effective.

For uses that are genuinely off-label, the appeal strategy focuses on demonstrating that the use is supported by established, peer-reviewed medical evidence and recognized professional society guidelines. Many plan documents and state laws require coverage of off-label uses that meet this standard.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer-sponsored plans) or applicable state law (individual and fully-insured plans), you have the right to a full-and-fair internal review. File within the deadline stated on your denial notice.
• External review: Under ACA §2719, an independent review organization (IRO) can review whether the experimental finding is accurate and whether the evidence standard is met. The external-review window is generally approximately four months from the final internal denial; confirm the exact date on your denial letter.
• Expedited review: Request expedited processing if delay would seriously jeopardize your health or ability to function.

## Documentation to Gather

1. FDA prescribing label: The complete, current FDA-approved prescribing information for semaglutide. Identify and highlight the specific approved indication that corresponds to your diagnosis. This is your most powerful document if the use is on-label. 2. Diagnosis documentation: Chart records confirming your diagnosis, including objective clinical findings, diagnosis date, and the treating provider's assessment — establishing that your diagnosis falls within the FDA-approved or evidence-supported use. 3. Professional society guideline reference: The name of the relevant clinical guideline organization (such as the American Diabetes Association, the Obesity Society, the American Heart Association, or other applicable body) that includes semaglutide as a recognized option for your indication. Do not cite specific numeric thresholds — reference the organization and the guideline document by name and year. 4. Prescriber medical-necessity letter: A detailed, signed letter from your physician explaining the clinical rationale for the prescription, citing the FDA approval status and professional society recognition. 5. Humana's policy language: Obtain Humana's current clinical policy for semaglutide and for experimental/investigational drug coverage. Identify exactly how the policy defines experimental and address each element of that definition.

## Criteria-Mapping Structure

Address Humana's specific experimental-coverage criteria point by point:

| Humana Experimental Criterion (from policy) | Your Rebuttal Evidence | |---------------------------------------------|------------------------| | Is the use FDA-approved for this indication? | [FDA approval date and indication from the prescribing label] | | Is the use recognized by an applicable professional society guideline? | [Guideline organization name, document title, year — no numeric thresholds] | | Is there peer-reviewed published evidence supporting the use? | [Prescriber attestation referencing the evidence base, no specific trial names or statistics] | | Does the use meet Humana's definition of established therapy? | [Point-by-point response to each element of Humana's policy definition] |

When the FDA has already approved the use, an experimental denial from any insurer is particularly vulnerable to reversal on appeal. Present the FDA label clearly and request an expedited response.